COMMUNIQUÉS West-GlobeNewswire

Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
30/09/2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies [...]
Precision Optics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
30/09/2024
Conference Call Scheduled for today, September 30, 2024, at 5:00pm ET. GARDNER, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of [...]
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
30/09/2024
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator — — The [...]
Biocodex Microbiota Foundation Invites Canadian Academics and Scientists to Apply for €25,000 Research Grant to Advance Microbiota’s role Study in health and diseases
30/09/2024
MONTREAL, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant [...]
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
30/09/2024
Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise monitoring of low- [...]
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
30/09/2024
2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better [...]
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
30/09/2024
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk [...]
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
30/09/2024
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
30/09/2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at [...]
The Pennant Group Announces Public Offering of Common Stock
30/09/2024
EAGLE, Idaho, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG) (the “Company”) today announced that it has commenced an underwritten public offering of 3,500,000 shares of common stock of the [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30/09/2024
WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
30/09/2024
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., [...]
Galapagos receives transparency notification from EcoR1 Capital
30/09/2024
Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency [...]
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
30/09/2024
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers [...]
Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2025 Financial Results on October 10, 2024
30/09/2024
NEW YORK and LEAMINGTON, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, today [...]
Laguna Treatment Center Expands Offerings with Equine Therapy and Breathwork
30/09/2024
ALISO VIEJO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Laguna Treatment Center, a leading Southern California-based addiction treatment facility, has expanded its treatment options to include breathwork and equine [...]
AB Science announces a slight delay in the publication of its 2024 half-year financial report
30/09/2024
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2024 HALF-YEAR FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2024 ON OCTOBER 7, 2024 Paris, September 30 2024, 6 [...]
AB Science annonce un léger décalage de la publication de son rapport financier du premier semestre 2024
30/09/2024
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE UN LEGER DECALAGE DE LA PUBLICATION DE SON RAPPORT FINANCIER SEMESTRIEL 2024 LA SOCIETE PUBLIERA SON RAPPORT FINANCIER SEMESTRIEL 2024 LE 7 OCTOBRE 2024 Paris, 30 septembre 2024, [...]
Eurobio Scientific : COMMUNIQUÉ DU 30 SEPTEMBRE 2024 EN RÉPONSE AU PROJET D’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE EUROBIO SCIENTIFIC S.A. INITIÉE PAR LA SOCIÉTÉ EB DEVELOPMENT
30/09/2024
COMMUNIQUÉ DU 30 SEPTEMBRE 2024 RELATIF AU DÉPÔT DU PROJET DE NOTE D’INFORMATION ÉTABLI PAR LA SOCIÉTÉ Eurobio Scientific EN RÉPONSE AU PROJET D’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE EUROBIO SCIENTIFIC S.A. [...]

Pages